She lost 10kg of muscle and gained fat: The hidden risk of weight-loss drugs
Résumé détaillé
Sydney doctor Dr Kean-Seng Lim’s waiting room is a stark reminder of the great potential, and the potential risks, of GLP-1s.
At a Mount Druitt medical practice where four in five patients are overweight and obese, a woman struggles to rise from her chair, her muscles having wasted away.
Dr Kean-Seng Lim’s western Sydney waiting room is a stark reminder of the great potential, and potential risks of GLP-1s such as Wegovy and Ozempic (semaglutide).
“They are powerful tools if used well, but they can be a double-edged sword,” said Lim, a GP for more than 30 years and a former Australian Medical Association NSW president.
A surge in demand for GLP-1 medications is expected to accelerate, with the first two oral GLP-1s – Novo Nordisk’s Wegovy pill and Lilly’s Foundayo – arriving at pharmacies for patients with private prescriptions.
GLP-1s, approved for chronic weight management when combined with diet and exercise, can be life-changing, triggering significant weight loss and lowering the risk of obesity-related health complications. Semaglutides have also been shown to lower the risk of heart attack, stroke and cardiovascular death.
But clinicians and researchers have cautioned against mistaking GLP-1s for a silver bullet, warning muscle wastage and a great weight rebound was on the horizon for those who do.
“But worryingly, the focus for these agents has been on weight, rather than health,” Lim said.
Kean-Seng recalled one of his patients, a woman aged over 60, who was having great difficulty getting out of her chair.
She had been prescribed GLP-1s via another provider with no follow-up or diet and exercise advice, reduced her food intake and, critically, wasn’t eating enough protein, Kean-Seng said.
Début de l'article, extrait de The Sydney Morning Herald. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.smh.com.au)


